U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use, Regions, And Segment Forecasts 2018 To 2024

Table of Content

Chapter 1 Research Methodology
1.1 Information procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 U.S.
2.1.1 U.S. next generation sequencing market, 2013 - 2024 (USD Million)
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
4.1 Market segmentation& scope
4.1.1 Market Driver Analysis
4.1.1.1 Exponentially decreasing costs for genetic sequencing
4.1.1.2 Growing related advancement of personalized medicine
4.1.1.3 Rise in competition amongst prominent market entities
4.1.1.4 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
4.1.1.5 Increasing prevalence of cancer
4.1.1.6 Growing adoption of NGS over single gene testing
4.1.2 Market Restraint Analysis
4.1.2.1缺乏computational efficiency for data management
4.1.2.2 Non-value based NGS reimbursement policy
4.2 Penetration & growth prospect mapping for applications, 2015
4.3 p渗透和增长rospect mapping for prominent industry players, 2015
4.4 NGS platform positioning, 2015
4.5 U.S. clinical oncology NGS company market share analysis, 2015
4.6 Next Generation Sequencing - SWOT Analysis, By Factor (political & legal, economic and technological)
4.7 Industry Analysis - Porter’s
4.8 Upcoming Developments Analysis in Oncology NGS
Chapter 5 Market Categorization 1: Technology Estimates & Trend Analysis
5.1 U.S. clinical oncology NGSmarket: Technology movement analysis
5.2 Targeted Sequencing & Resequencing
5.2.1 U.S. targeted sequencing & resequencingmarket, 2013 - 2024 (USD Million)
5.3 Whole Genome Sequencing
5.3.1 U.S. whole genome sequencingmarket, 2013 - 2024 (USD Million)
5.4 Whole Exome Sequencing
5.4.1 U.S. whole exomesequencing market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Workflow Estimates & Trend Analysis
6.1 U.S. clinical oncology NGS market: Workflow movement analysis
6.2 NGS Pre-Sequencing
6.2.1 U.S.NGS pre-sequencingmarket, 2013 - 2024 (USD Million)
6.3 NGS Sequencing
6.3.1 U.S.NGS sequencingmarket, 2013 - 2024 (USD Million)
6.4 NGS Data Analysis
6.4.1 U.S. NGS data analysis2013 - 2024 (USD Million)
6.4.2 NGS Primary Data Analysis
6.4.2.1 U.S.NGS primary data analysis market, 2013 - 2024 (USD Million)
6.4.3 NGS Secondary Data Analysis
6.4.3.1 U.S.NGS secondary data analysis, 2013 - 2024 (USD Million)
6.4.4 NGS Tertiary Data Analysis
6.4.4.1 U.S.NGS tertiary data analysisservices market, 2013 - 2024 (USD Million)
Chapter 7 Market Categorization 3: End-use Estimates & Trend Analysis
7.1 U.S. Clinical Oncology NGSmarket: End-use movement analysis
7.2 Academic Research
7.2.1 U.S.academic researchmarket, 2013 - 2024 (USD Million)
7.3 Clinical Research
7.3.1 U.S.clinical researchmarket, 2013 - 2024 (USD Million)
7.4 Hospitals & Clinics
7.4.1 U.S.hospitals & clinics market2013 - 2024 (USD Million)
7.5 Pharma & Biotech Entities
7.5.1 U.S.pharma & biotech entitiesmarket, 2013 - 2024 (USD Million)
7.6 Other users
7.6.1 U.S.other usersmarket, 2013 - 2024 (USD Million)
Chapter 8 Market Categorization 4: Regional Estimates & Trend Analysis, by Technology, Workflow&End-use
Chapter 9 Competitive Landscape
9.1 Strategy framework
9.2 Market participation categorization
9.3 Company Profiles
9.3.1 Illumina Incorporated
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2罗氏Sequencing (454 Life Sciences)
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 Agilent Technologies
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 Knome Inc.
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 Genomatix Software GmbH
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 GATC Biotech Ag
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 Oxford Nanopore Technologies Ltd.
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 Macrogen Inc.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 Life Technologies Corp.
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 DNASTAR Inc.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 Myriad Genetics
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.3.12 Exosome Diagnostics, Inc.
9.3.12.1 Company Overview
9.3.12.2 Financial Performance
9.3.12.3 Product Benchmarking
9.3.12.4 Strategic Initiatives
9.3.13 Biomatters Ltd.
9.3.13.1 Company Overview
9.3.13.2 Financial Performance
9.3.13.3 Product Benchmarking
9.3.13.4 Strategic Initiatives
9.3.14 Life CLC Bio
9.3.14.1 Company Overview
9.3.14.2 Financial Performance
9.3.14.3 Product Benchmarking
9.3.14.4 Strategic Initiatives
9.3.15 BGI (Complete Genomics)
9.3.15.1 Company Overview
9.3.15.2 Financial Performance
9.3.15.3 Product Benchmarking
9.3.15.4 Strategic Initiatives
9.3.16 Qiagen NV
9.3.16.1 Company Overview
9.3.16.2 Financial Performance
9.3.16.3 Product Benchmarking
9.3.16.4 Strategic Initiatives
9.3.17 Perkin Elmer, Inc.
9.3.17.1 Company Overview
9.3.17.2财务业绩
9.3.17.3 Product Benchmarking
9.3.17.4 Strategic Initiatives
9.3.18 Pacific Bioscience, Inc.
9.3.18.1 Company Overview
9.3.18.2 Financial Performance
9.3.18.3 Product Benchmarking
9.3.18.4 Strategic Initiatives
9.3.19 Partek, Inc.
9.3.19.1 Company Overview
9.3.19.2 Financial Performance
9.3.19.3 Product Benchmarking
9.3.19.4 Strategic Initiatives
9.3.20 GnuBIO (Bio-Rad)
9.3.20.1 Company Overview
9.3.20.2 Financial Performance
9.3.20.3 Product Benchmarking
9.3.20.4 Strategic Initiatives
9.3.21 Foundation Medicine Inc.
9.3.21.1 Company Overview
9.3.21.2 Financial Performance
9.3.21.3 Product Benchmarking
9.3.21.4 Strategic Initiatives
9.3.22 Paradigm Diagnostics, Inc
9.3.22.1 Company Overview
9.3.22.2 Financial Performance
9.3.22.3 Product Benchmarking
9.3.22.4 Strategic Initiatives
9.3.23 Caris Life Sciences
9.3.23.1 Company Overview
9.3.23.2 Financial Performance
9.3.23.3 Product Benchmarking
9.3.23.4 Strategic Initiatives

List of Tables

TABLE 1 Healthcare expenditure levels, 2012
TABLE 2 North America cancer incidences in 2012
TABLE 3 U.S. clinical oncology NGS market estimates, by technology, 2013 - 2015 (USD Million)
TABLE 4 U.S. clinical oncology NGS market forecasts, by technology, 2016 - 2024 (USD Million)
TABLE 5 U.S. clinical oncology NGS market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 6 U.S. clinical oncology NGS market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 7 U.S. clinical oncology NGS data analysis market estimates, by workflow, 2013 - 2015 (USD Million)
TABLE 8 U.S. clinical oncology NGS data analysis market forecasts, by workflow, 2016 - 2024 (USD Million)
TABLE 9 U.S. clinical oncology NGS market estimates, by end use, 2013 - 2015 (USD Million)
TABLE 10 U.S. clinical oncology NGS market forecasts, by end use, 2016- 2024 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 U.S. next generation sequencing market, 2013 - 2024 (USD million)
FIG. 8 Market summary
FIG. 9 Market trends & outlook
FIG. 10 Market segmentation & scope
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Cost per raw mega base (Mb) of DNA sequence (USD)
FIG. 13 Cost per genome
FIG. 14 Expected rise in expenditure for cancer treatment (USD Billion)
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Penetration & growth prospect mapping for applications, 2015
FIG. 17 Penetration & growth prospect mapping for prominent industry players, 2015
FIG. 18 NGS platform positioning, 2015
FIG. 19 U.S. clinical oncology NGS company market share analysis, 2015
FIG. 20 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 21 Porter’s Five Forces Analysis
FIG. 22 U.S. clinical oncology NGS market: Technology outlook key takeaways
FIG. 23 U.S. clinical oncology NGS market: Technology movement analysis
FIG. 24 U.S.targeted sequencing & resequencing market, 2013 - 2024 (USD Million)
FIG. 25 U.S. whole genome sequencing market, 2013 - 2024 (USD Million)
FIG. 26 U.S. whole exome sequencing market, 2013 - 2024 (USD Million)
FIG. 27 U.S. clinical oncology NGS market workflow outlook key takeaways
FIG. 28 Next generation sequencing market: workflow movement analysis
FIG. 29 U.S. NGS pre-sequencing market, 2013 - 2024 (USD Million)
FIG. 30 U.S. NGS Sequencingmarket, 2013 - 2024 (USD Million)
FIG. 31 U.S. NGS data analysis market, 2013 - 2024 (USD Million)
FIG. 32 U.S. NGS primary data analysis market, 2013 - 2024 (USD Million)
FIG. 33 U.S. NGS secondary data analysis market, 2013 - 2024 (USD Million)
FIG. 34 U.S. NGS tertiary data analysis market, 2013 - 2024 (USD Million)
FIG. 35 U.S. clinical oncology NGS market end-use outlook key takeaways
FIG. 36 Next generation sequencing market: End-use movement analysis
FIG. 37 U.S. academic research market, 2013 - 2024 (USD Million)
FIG. 38 U.S. clinical research market, 2013 - 2024 (USD Million)
FIG. 39 U.S. hospitals & clinics market, 2013 - 2024 (USD Million)
FIG. 40 U.S. pharma & biotech entities market, 2013 - 2024 (USD Million)
FIG. 41 U.S. other users market, 2013 - 2024 (USD Million)
FIG. 42 Strategy framework
FIG. 43 Participant categorization